ALGN
Align Technology, Inc.
ALGN has a slight edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
ALGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
ALGN's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALGN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $167 | — |
| Current | 24x | $167 | — |
| Cheap | 25x | $173 | +3.5% |
| Fair | 35x | $242 | +45% |
| Expensive | 69x | $470 | +182% |
Historical ranges are pointers, not guarantees.
ALGN's PE is in its cheap range at 24x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ALGN in the historical PE scenario, which offers more potential upside but is not a forecast.
ALGN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect ALGN's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ALGN on the outlook, with more favorable revenue expectations.
ALGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.89 | +73% |
| Q3 2026 | $6.86 | +33% |
| Q2 2026 | $5.74 | -3.4% |
| Q1 2026 | $5.95 | +8.2% |
| Q4 2025 | $5.65 | +0.5% |
| Q3 2025 | $5.17 | -12% |
| Q2 2025 | $5.94 | +1% |
| Q1 2025 | $5.50 | -9.2% |
| Q4 2024 | $5.62 | -3.3% |
ALGN's earnings per share have fallen from their peak: $6.86 over the past year, against $23.85 in early 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ALGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +1.9% |
| Q2 2026 | $1.1B | +4.3% |
| Q1 2026 | $1B | +6.2% |
| Q4 2025 | $1B | +5.3% |
| Q3 2025 | $995.7M | +1.8% |
| Q2 2025 | $1B | -1.6% |
| Q1 2025 | $979.3M | -1.8% |
| Q4 2024 | $995.2M | +4% |
ALGN's revenue has grown year over year for five quarters in a row: $1B last quarter, up 1.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +7 points |
| Q2 2026 | 15% | -1.5 points |
| Q1 2026 | 14% | +0.3 points |
| Q4 2025 | 15% | +0.3 points |
| Q3 2025 | 9.7% | -6.9 points |
| Q2 2025 | 16% | +1.8 points |
| Q1 2025 | 13% | -2.1 points |
| Q4 2024 | 14% | -3.4 points |
ALGN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ALGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ALGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $137.9M | -18% |
| Q2 2026 | $157.1M | +47% |
| Q1 2026 | $120.3M | +339% |
| Q4 2025 | $187.3M | -29% |
| Q3 2025 | $169M | -28% |
| Q2 2025 | $107.2M | +0.7% |
| Q1 2025 | $27.4M | +42% |
| Q4 2024 | $263.1M | +1851% |
ALGN still generates free cash flow, though less than at its 2020 peak: $603M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ALGN on cash flow, with more consistent year-over-year improvement.
ALGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -505K shares |
| 1 year | -1.9% | -1.4M shares |
| 3 years | -7.6% | -5.8M shares |
| 5 years | -11% | -8.5M shares |
| Available history | -11% | -9.1M shares |
ALGN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $103.1M |
| Q2 2026 | $66.9M |
| Q1 2026 | $31.2M |
| Q4 2025 | $97.2M |
| Q3 2025 | $71.6M |
| Q2 2025 | $96M |
| Q1 2025 | $201.1M |
| Q4 2024 | $202.9M |
ALGN spent $298M buying back its own shares over the past year, down 48% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ALGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.3x | Net Cash |
| Q2 2026 | -1.4x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.2x | Net Cash |
| Q1 2025 | -1.2x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
ALGN has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ALGN on leverage, with a lower net debt burden relative to earnings.
ALGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.6 | Neutral |
| Stochastic | 50.8 | Neutral |
ALGN's weekly RSI is 54 (neutral) and its Stochastic is 51 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ALGN PE vs Healthcare Sector
| Metric | ALGN | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 26x | 5.8% below |
| PE % | 16 | 29 | 13 pts below |
ALGN is trading at 24x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ALGN on valuation relative to its sector.
ALGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $152.2 | 9.7% above |
| 20 week MA | $161.4 | 3.5% above |
| 50 week MA | $168.0 | 0.6% below |
| 100 week MA | $169.4 | 1.4% below |
| 200 week MA | $225.1 | 26% below |
ALGN has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 26% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ALGN on trend strength, trading above more of its moving averages.
ALGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $277.6 | $528.0 | +90% |
| 2021 | $528.0 | $654.0 | +24% |
| 2022 | $654.0 | $203.7 | -69% |
| 2023 | $203.7 | $274.0 | +35% |
| 2024 | $274.0 | $211.4 | -23% |
| 2025 | $211.4 | $158.4 | -25% |
| 2026 YTD | $158.4 | $167.0 | +5.4% |
ALGN has finished lower in three of the last six years. It's up 5.4% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ALGN on returns for 2026, with the stronger performance.